VanEck Pharmaceutical ETF

PPH

Market cap $1.34B

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and diabetes, outpacing Novo Nordisk, which faces a sharp 2026 revenue decline amid fierce competition, pricing pressure, and other factors.

Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.

The VanEck Pharmaceutical ETF ( NYSEARCA:PPH ) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution.

The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.

The VanEck Pharmaceutical ETF offers concentrated exposure to large-cap global pharma leaders, balancing growth, defensive, and non-drug cash flow stabilizers. PPH has demonstrated resilience, outperforming during market drawdowns and delivering an ~11.2% CAGR over five years with lower volatility than the S&P 500. The ETF's structure avoids excessive mega-cap or early-stage risk, with performance driven by earnings, product cycles, and disciplined capital allocation.

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.

The price cuts will save Medicare billions of dollars in prescription-drug spending.